The role of monoclonal antibodies in the treatment of lupus nephritis. (PubMed, Expert Opin Biol Ther) - Apr 8, 2026 - "We summarize updates in international guidelines, including the 2025 EULAR recommendations, which incorporate biologic and targeted agents such as obinutuzumab and voclosporin into standard treatment regimens and promote combination strategies to improve efficacy while limiting cumulative toxicity. In addition, we review data from recent clinical trials evaluating novel agents, including telitacicept, baricitinib, and dapirulizumab, as well as early-stage and experimental approaches such as CAR T-cell therapies...The therapeutic landscape of lupus nephritis is rapidly evolving, with promising new agents expanding available options; however, high costs, limited access, and insufficient long-term data currently restrict their widespread first-line use. Future head-to-head trials and real-world studies are essential to refine treatment algorithms and improve durable renal outcomes."
Journal • Review • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Blanca Viejo-Sosa; David Isenberg; Mònica Angerri-Nadal; Roni Meidan; Uxía Couto-Lareo
|